Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2017
Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial.
Open access · greenAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 53 citations in OpenAlex.
- Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Trial
- A tumor profiling resource for ovarian cancer: insights into chemotherapy-driven heterogeneity and personalized treatment strategy.Nature communications · 2026Article
- Targeting the FGF19/FGFR4 positive feedback loop to disrupt ERK-mediated tumor progression in head and neck cancer.Journal of translational medicine · 2026Article
- Causal relationship between palmitoylation genes mediated by immune cell phenotypes and oral cancer: A Mendelian randomized study.Medicine · 2025Article
- Molecular and Genetic Pathogenesis of Oral Cancer: A Basis for Customized Diagnosis and Treatment.Biology · 2025Review
- Identification of HES4 as a novel prognostic marker and therapeutic target in hepatocellular carcinoma.Discover oncology · 2025Article
- MYC Overexpression Enhances Sensitivity to MEK Inhibition in Head and Neck Squamous Cell Carcinoma.International journal of molecular sciences · 2025Article
- CD44 variant exons induce chemoresistance by modulating cell death pathways.Frontiers in cell and developmental biology · 2025Review
- Article
- Mucocutaneous toxicities from MEK inhibitors: a scoping review of the literature.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer.Molecular oncology · 2023Article
- Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect.Journal of translational medicine · 2023Review
- Review
- Functional proteomics of patient derived head and neck squamous cell carcinoma cells reveal novel applications of trametinib.Cancer biology & therapy · 2022Article
- Article
- Trametinib improves Treg selectivity of anti-CCR4 antibody by regulating CCR4 expression in CTLs in oral squamous cell carcinoma.Scientific reports · 2022Article
- MAPK Signaling Pathway in Oral Squamous Cell Carcinoma: Biological Function and Targeted Therapy.Cancers · 2022Review
- A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma.Nature communications · 2022Article
- The mouse oral carcinoma (MOC) model: A 10-year retrospective on model development and head and neck cancer investigations.Oral oncology · 2022Review
- Genomic Hippo Pathway Alterations and Persistent YAP/TAZ Activation: New Hallmarks in Head and Neck Cancer.Cells · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 2 institutions in 2 countries.
Ravindra UppaluriAlvin J. Siteman Cancer Center, Washington University in St. Louis, St. Louis, Missouri. Ravindra_Uppaluri@DFCI.Harvard.edu.
Ashley E WinklerDepartment of Otolaryngology, Washington University in St. Louis, St. Louis, Missouri.
Tianxiang LinDepartment of Otolaryngology, Washington University in St. Louis, St. Louis, Missouri.
Jonathan H LawAlvin J. Siteman Cancer Center, Washington University in St. Louis, St. Louis, Missouri.
Bruce H HaugheyAlvin J. Siteman Cancer Center, Washington University in St. Louis, St. Louis, Missouri.
Brian NussenbaumAlvin J. Siteman Cancer Center, Washington University in St. Louis, St. Louis, Missouri.
Randal C PanielloAlvin J. Siteman Cancer Center, Washington University in St. Louis, St. Louis, Missouri.
Jason T RichAlvin J. Siteman Cancer Center, Washington University in St. Louis, St. Louis, Missouri.
Jason A DiazAlvin J. Siteman Cancer Center, Washington University in St. Louis, St. Louis, Missouri.
Loren P MichelAlvin J. Siteman Cancer Center, Washington University in St. Louis, St. Louis, Missouri.
Tanya WildesAlvin J. Siteman Cancer Center, Washington University in St. Louis, St. Louis, Missouri.
Gavin P DunnAlvin J. Siteman Cancer Center, Washington University in St. Louis, St. Louis, Missouri.
Paul ZolkindDepartment of Otolaryngology, Washington University in St. Louis, St. Louis, Missouri.
Dorina KallogjeriDepartment of Otolaryngology, Washington University in St. Louis, St. Louis, Missouri.
Jay F PiccirilloAlvin J. Siteman Cancer Center, Washington University in St. Louis, St. Louis, Missouri.
Farrokh DehdashtiAlvin J. Siteman Cancer Center, Washington University in St. Louis, St. Louis, Missouri.
Barry A SiegelAlvin J. Siteman Cancer Center, Washington University in St. Louis, St. Louis, Missouri.
Rebecca D ChernockDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri.
James S LewisDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee.
Douglas R AdkinsAlvin J. Siteman Cancer Center, Washington University in St. Louis, St. Louis, Missouri.
Washington University in St. Louis · USVanderbilt University Medical Center · US
Funding
Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0MDEVELOPMENT OF CLINICIAN/RESEARCHERS IN ACADEMIC ENTT32DC000022 · NIDCD · WASHINGTON UNIVERSITY · PI PICCIRILLO, JAY F. · 1989 to 2022
$5.6MGENOMIC INSIGHTS AND THERAPEUTIC TARGETING OF ORAL CANCER TUMOR INITIATING CELLSR01DE024403 · NIDCR · WASHINGTON UNIVERSITY · PI UPPALURI, RAVINDRA · 2014 to 2018
$1.9MNCI NIH HHS P30 CA091842NIDCD NIH HHS T32 DC000022NIDCR NIH HHS R01 DE024403
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedBiomarkers, TumorCarcinoma, Squamous CellDrug-Related Side Effects and Adverse ReactionsFemaleGene Expression Regulation, NeoplasticHumansHyaluronan ReceptorsMaleMAP Kinase Signaling SystemMiddle AgedMouthMouth NeoplasmsNeoadjuvant TherapyNeoplasm StagingBiomarkers, TumorCD44 protein, humanHyaluronan ReceptorsProtein Kinase InhibitorsPyridonesPyrimidinonestrametinib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.